· Last Round Valuation (2021) : ~$400 Million

· H1 2023 Revenue (Unaudited) / 2023: $10Billion

· H1 2023 Net Profit (Unaudited) / 2023: $95 Million

We are proud to be supported by a consortium of savvy investors who believe in our vision and model.

Lead Investors in Recent Rounds

· Series C (2021): Co-led by "MedVenture Partners" and "Life Sciences Growth Fund".

· Series B (2015): Led by "Cross-Pacific Healthcare Fund".

Our board includes representatives from these firms, providing invaluable strategic guidance.

For Prospective Investors

We are always open to connecting with serious investors who understand the medtech space and are interested in the value we are building. We have a dedicated data room for due diligence. Actively exploring strategic options, including a potential public listing in the next 24-36 months.

We Might Be a Fit If You Are ：A sector-focused VC or Growth Equity firm looking for companies with proven products and clear paths to profitability. Strategic corporate venture arm looking to partner with or acquire innovative technologies in our field. Family office or institutional investor seeking exposure to the high-growth Asian healthcare market through a seasoned management team.

Contact :

Sarah Chen, Head of Corporate Development

Email : partnerships@goldeneagle.com